William Blair restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a report released on Monday morning. William Blair also issued estimates for Krystal Biotech’s FY2018 earnings at ($0.93) EPS, FY2019 earnings at ($1.54) EPS, FY2020 earnings at ($1.91) EPS, FY2021 earnings at ($1.80) EPS and FY2022 earnings at ($2.22) EPS.
Several other brokerages have also recently commented on KRYS. Zacks Investment Research cut shares of Krystal Biotech from a buy rating to a hold rating in a research report on Wednesday, October 17th. HC Wainwright boosted their target price on shares of Krystal Biotech from $32.00 to $35.50 and gave the company a buy rating in a research report on Monday, October 15th. Cantor Fitzgerald assumed coverage on shares of Krystal Biotech in a research report on Monday, September 10th. They issued an overweight rating and a $28.00 target price for the company. LADENBURG THALM/SH SH set a $38.00 target price on shares of Krystal Biotech and gave the company a buy rating in a research report on Thursday, July 19th. Finally, ValuEngine upgraded shares of Krystal Biotech from a hold rating to a buy rating in a research report on Friday, September 21st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $31.60.
Krystal Biotech stock traded down $0.49 during midday trading on Monday, hitting $21.25. The company’s stock had a trading volume of 704 shares, compared to its average volume of 169,436. The stock has a market capitalization of $311.67 million, a price-to-earnings ratio of -14.53 and a beta of -0.81. Krystal Biotech has a 1-year low of $8.03 and a 1-year high of $24.89.
In other news, insider Krish S. Krishnan bought 25,000 shares of the company’s stock in a transaction dated Thursday, October 18th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $500,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 45.80% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC increased its position in Krystal Biotech by 552.2% during the 2nd quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock worth $182,000 after purchasing an additional 10,331 shares in the last quarter. BlackRock Inc. increased its position in Krystal Biotech by 75.4% during the 2nd quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after purchasing an additional 5,607 shares in the last quarter. P.A.W. Capital Corp acquired a new position in Krystal Biotech during the 3rd quarter worth approximately $527,000. Finally, JPMorgan Chase & Co. increased its position in Krystal Biotech by 69.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock worth $635,000 after purchasing an additional 14,755 shares in the last quarter. Institutional investors and hedge funds own 22.04% of the company’s stock.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Read More: What factors cause inflation to rise?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.